Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

Y0001576

Oxcarbazepine

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide, Oxacarbazepine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C15H12N2O2
Número de CAS:
28721-07-5
Peso molecular:
252.27
MDL number:
MFCD00865307
UNSPSC Code:
41116107
PubChem Substance ID:
329831491
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

oxcarbazepine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1CC2=C(C=CC=C2)N(C(N)=O)C3=CC=CC=C31

InChI

1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)

InChI key

CTRLABGOLIVAIY-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxcarbazepine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Anticonvulsant, antineuralgic. Inhibits veratrine-induced transmitter release.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Referencia del producto
Descripción
Precios

1483152

Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard

Y0001549

Oxcarbazepine impurity mixture, European Pharmacopoeia (EP) Reference Standard

1483185

Oxcarbazepine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1483200

Oxcarbazepine Related Compound E, United States Pharmacopeia (USP) Reference Standard

1483196

Oxcarbazepine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1483174

Oxcarbazepine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1483163

Oxcarbazepine Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR2238

Oxcarbazepine Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3071

Oxcarbazepine Related Compound C, pharmaceutical secondary standard, certified reference material

PHR3294

Licarbazepine, pharmaceutical secondary standard, certified reference material

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Gaetano Zaccara et al.
Seizure, 22(7), 528-536 (2013-04-30)
Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials. Indirect comparisons of patients withdrawing because of AEs, and the incidence of some vestibulocerebellar AEs between these three
Wetid Pratoomsri et al.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 51(8), 540-545 (2006-08-29)
To review the data on the efficacy of oxcarbazepine (OXC) in bipolar disorder (BD) and to provide recommendations for clinicians on the use of this medication in treating BD. Using the terms oxcarbazepine and bipolar disorder, oxcarbazepine and mania, or
Marianna Mazza et al.
Expert opinion on pharmacotherapy, 8(5), 649-656 (2007-03-23)
Oxcarbazepine (OXC) is a keto-congener of carbamazepine, which has fewer side effects and drug interactions. However, the efficacy of OXC in treating bipolar disorder is not as well established as that of carbamazepine. This article is a systematic literature review
Penny Bring et al.
Clinical pharmacokinetics, 47(12), 767-778 (2008-11-26)
Oxcarbazepine, the 10-keto analogue of carbamazepine, is approved for the treatment of partial seizures or generalized tonic-clonic seizures. The primary metabolite of oxcarbazepine is monohydroxylated derivative (MHD). This review follows a decision-making algorithm to determine if therapeutic drug monitoring of
Wassim Nasreddine et al.
Expert opinion on investigational drugs, 16(10), 1615-1625 (2007-10-10)
Neuropathic pain is a frequent condition that can result from a variety of underlying conditions and is frequently chronic and difficult to treat. A number of drugs are used to treat neuropathic pain, including anticonvulsants and antidepressants. Oxcarbazepine, a recently
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico